Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $503.70 million. The enterprise value is $831.45 million.
| Market Cap | 503.70M |
| Enterprise Value | 831.45M |
Important Dates
The last earnings date was Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 66.89 million shares outstanding. The number of shares has increased by 5.89% in one year.
| Current Share Class | 66.89M |
| Shares Outstanding | 66.89M |
| Shares Change (YoY) | +5.89% |
| Shares Change (QoQ) | +3.83% |
| Owned by Insiders (%) | 2.54% |
| Owned by Institutions (%) | 37.91% |
| Float | 34.88M |
Valuation Ratios
The trailing PE ratio is 271.92 and the forward PE ratio is 10.72.
| PE Ratio | 271.92 |
| Forward PE | 10.72 |
| PS Ratio | 0.88 |
| Forward PS | 0.86 |
| PB Ratio | 3.12 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.77 |
| P/OCF Ratio | 13.90 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.46, with an EV/FCF ratio of 24.38.
| EV / Earnings | 448.94 |
| EV / Sales | 1.47 |
| EV / EBITDA | 13.46 |
| EV / EBIT | 19.07 |
| EV / FCF | 24.38 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 1.79.
| Current Ratio | 1.48 |
| Quick Ratio | 0.89 |
| Debt / Equity | 1.79 |
| Debt / EBITDA | 5.39 |
| Debt / FCF | 10.58 |
| Interest Coverage | 1.30 |
Financial Efficiency
Return on equity (ROE) is 1.39% and return on invested capital (ROIC) is 4.71%.
| Return on Equity (ROE) | 1.39% |
| Return on Assets (ROA) | 3.64% |
| Return on Invested Capital (ROIC) | 4.71% |
| Return on Capital Employed (ROCE) | 8.37% |
| Revenue Per Employee | $606,604 |
| Profits Per Employee | $1,991 |
| Employee Count | 930 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 1.99 |
Taxes
In the past 12 months, Bioventus has paid $2.09 million in taxes.
| Income Tax | 2.09M |
| Effective Tax Rate | 43.44% |
Stock Price Statistics
The stock price has decreased by -0.40% in the last 52 weeks. The beta is 0.83, so Bioventus's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | -0.40% |
| 50-Day Moving Average | 6.70 |
| 200-Day Moving Average | 8.99 |
| Relative Strength Index (RSI) | 64.44 |
| Average Volume (20 Days) | 520,693 |
Short Selling Information
The latest short interest is 1.80 million, so 2.69% of the outstanding shares have been sold short.
| Short Interest | 1.80M |
| Short Previous Month | 1.59M |
| Short % of Shares Out | 2.69% |
| Short % of Float | 5.16% |
| Short Ratio (days to cover) | 4.33 |
Income Statement
In the last 12 months, Bioventus had revenue of $564.14 million and earned $1.85 million in profits. Earnings per share was $0.03.
| Revenue | 564.14M |
| Gross Profit | 381.35M |
| Operating Income | 43.61M |
| Pretax Income | -48.54M |
| Net Income | 1.85M |
| EBITDA | 61.78M |
| EBIT | 43.61M |
| Earnings Per Share (EPS) | $0.03 |
Balance Sheet
The company has $32.91 million in cash and $360.66 million in debt, giving a net cash position of -$327.75 million or -$4.90 per share.
| Cash & Cash Equivalents | 32.91M |
| Total Debt | 360.66M |
| Net Cash | -327.75M |
| Net Cash Per Share | -$4.90 |
| Equity (Book Value) | 201.30M |
| Book Value Per Share | 2.41 |
| Working Capital | 89.52M |
Cash Flow
In the last 12 months, operating cash flow was $36.25 million and capital expenditures -$2.15 million, giving a free cash flow of $34.10 million.
| Operating Cash Flow | 36.25M |
| Capital Expenditures | -2.15M |
| Free Cash Flow | 34.10M |
| FCF Per Share | $0.51 |
Margins
Gross margin is 67.60%, with operating and profit margins of 7.73% and 0.33%.
| Gross Margin | 67.60% |
| Operating Margin | 7.73% |
| Pretax Margin | 0.85% |
| Profit Margin | 0.33% |
| EBITDA Margin | 10.95% |
| EBIT Margin | 7.73% |
| FCF Margin | 6.04% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.89% |
| Shareholder Yield | -5.89% |
| Earnings Yield | 0.37% |
| FCF Yield | 6.77% |
Analyst Forecast
The average price target for Bioventus is $14.40, which is 91.24% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.40 |
| Price Target Difference | 91.24% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 1.19 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.19 |
| Piotroski F-Score | 8 |